Role for HLA in susceptibility to infectious mononucleosis

Journal of Clinical Investigation

Volumn 117, Issue 10, 2007, Pages 2756-2758

  Farrell, Paul J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS VACCINE;

ALLELE; B LYMPHOCYTE; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE SEQUENCE; GENETIC PREDISPOSITION; HLA SYSTEM; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE; VIRUS INFECTION;

GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HERPESVIRUS VACCINES; HLA ANTIGENS; HUMANS; INFECTIOUS MONONUCLEOSIS;

EID: 34948829187     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33563     Document Type: Review

References (20)

1. Rickinson, A.B., and Kieff, E. 2001. Epstein-Barr virus. In Fields virology. D. Knipe and P.M. Howley, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 2575-2627.
2. Thorley-Lawson, D.A., and Gross, A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337.
3. Mancao, C., and Hammerschmidt, W. 2007. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. In press.
4. Laichalk, L.L., and Thorley-Lawson, D.A. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79:1296-1307.
5. Hislop, A.D., Taylor, G.S., Sauce, D., and Rickinson, A.B. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25:587-617.
6. Sauce, D., et al. 2006. EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Blood. 108:11-18.
7. Hjalgrim, H., et al. 2003. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N. Engl. J. Med. 349:1324-1332.
8. Hjalgrim, H. 2007. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67:2382-2388.
9. Jarrett, R.F., et al. 2005. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 106:2444-2451.
10. Young, L.S., and Murray, P.G. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 22:5108-5121.
11. McAulay, K.A., et al. 2007. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J. Clin. Invest. 117:3042-3048. doi:10.1172/JCI32377.
12. Diepstra, A., et al. 2005. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet. 365:2216-2224.
13. Niens, M., et al. 2007. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV-positive Hodgkin lymphoma. Blood. In press.
14. Helminen, M., Lahdenpohja, N., and Hurme, M. 1999. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J. Infect. Dis. 180:496-499.
15. Wu, M.S., et al. 2002. Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J. Infect. Dis. 185:106-109.
16. Hurme, M., and Helminen, M. 1998. Polymorphism of the IL-1 gene complex in Epstein-Barr virus seronegative and seropositive adult blood donors. Scand. J. Immunol. 48:219-222.
17. Brauninger, A., et al. 2006. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int. J. Cancer. 118:1853-1861.
18. Crawford, D.H., et al. 2006. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin. Infect. Dis. 43:276-282.
19. Tierney, R.J., et al. 2006. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J. Infect. Dis. 193:287-297.
20. Moutschen, M., et al. 2007. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 25:4697-4705.